Literature DB >> 7594483

Constitutive production of IL-2 by human carcinoma cells, expression of IL-2 receptor, and tumor cell growth.

W C Lin1, S Yasumura, Y Suminami, M W Sung, S Nagashima, J Stanson, T L Whiteside.   

Abstract

Human carcinomas spontaneously express abundant IL-2R beta but little IL-2R alpha on the cell surface, contain mRNA for IL-2R beta- and IL-2R alpha-chains, and may be inhibited in growth by exogenous IL-2. To study the relationship between IL-2R expression and growth inhibition by IL-2, carcinoma cells were transduced with IL-2R alpha and IL-2R gamma cDNAs or IL-2R beta antisense cDNA. Transfectants with the IL-2R alpha gene expressed high levels of the alpha- and beta-receptor chains and showed increased binding of [125I]IL-2. Exogenous IL-2 at the picometer concentrations inhibited their growth, and Abs to IL-2R alpha- or IL-2R beta-chains reversed the inhibition. After transduction of IL-2R beta antisense cDNA, gastric carcinoma (HR) cells no longer expressed IL-2R beta-chain, and their proliferation was depressed in the absence of exogenous IL-2. Transduction of IL-2R gamma-chain cDNA into tumor cells increased sensitivity to growth inhibition by exogenous IL-2 of a squamous cell carcinoma line, but not of HR or renal cell carcinoma lines. All of the parental and transduced tumor cell lines were found to constitutively express intracellular IL-2, detectable by immunostaining or flow cytometry of permeabilized cells. IL-2 was present on the surface of some tumor cells. Intracellular IL-2R beta and IL-2R gamma proteins were also detectable in tumor cells. Using reverse-transcription PCR combined with Southern blots or in situ hybridization, mRNA for IL-2 was found to be present in parental and transduced tumor cells. Expression on human carcinomas of IL-2R beta, inhibition of their growth by IL-2R beta antisense cDNA, and their ability to constitutively produce IL-2 and its presence on the cell surface, all suggest that endogenous IL-2 may play a role in tumor cell growth.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594483

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.

Authors:  Christian M Capitini; Terry J Fry; Crystal L Mackall
Journal:  Am J Immunol       Date:  2009-01-01

2.  Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.

Authors:  M A Nash; R Lenzi; C L Edwards; J J Kavanagh; A P Kudelka; C F Verschraegen; C D Platsoucas; R S Freedman
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

3.  Prolactin receptor is a negative prognostic factor in patients with squamous cell carcinoma of the head and neck.

Authors:  T Bauernhofer; M Pichler; E Wieckowski; J Stanson; A Aigelsreiter; A Griesbacher; A Groselj-Strele; A Linecker; H Samonigg; C Langner; T L Whiteside
Journal:  Br J Cancer       Date:  2011-04-19       Impact factor: 7.640

4.  Interleukin 2 exerts autocrine stimulation on murine T-cell leukaemia growth.

Authors:  C I Waldner; C Mongini; E Alvarez; M Sánchez Lockhart; M J Gravisaco; S E Hajos
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  The role of endogenous interleukin-2 in proliferation of human carcinoma cell lines.

Authors:  T E Reichert; Y Kashii; J Stanson; A Zeevi; T L Whiteside
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

6.  Cytokine production in mammary adenocarcinoma and its microenvironmental cells in patients with or without metastases in regional lymph nodes.

Authors:  Alexander Autenshlyus; Sergey Arkhipov; Elena Mikhailova; Igor Marinkin; Valentina Arkhipova; Ekaterina Mogilnaya; Nikolay Varaksin; Michael Rukavishnikov
Journal:  Int J Immunopathol Pharmacol       Date:  2017-07-26       Impact factor: 3.219

7.  Interleukin-2 and its receptor complex (alpha, beta and gamma chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study.

Authors:  Ignacio García-Tuñón; Mónica Ricote; Antonio Ruiz; Benito Fraile; Ricardo Paniagua; Mar Royuela
Journal:  Breast Cancer Res       Date:  2003-10-22       Impact factor: 6.466

8.  Activation of the IL-2 Receptor in Podocytes: A Potential Mechanism for Podocyte Injury in Idiopathic Nephrotic Syndrome?

Authors:  Arnold H Zea; Tyrus Stewart; Jeannine Ascani; David J Tate; Beatriz Finkel-Jimenez; Anna Wilk; Krzysztof Reiss; William E Smoyer; Diego H Aviles
Journal:  PLoS One       Date:  2016-07-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.